What is Driving the Age-Related Macular Degeneration Market?

What is Driving the Age-Related Macular Degeneration Market?

The Age-Related Macular Degeneration (AMD) market is a crucial segment in ophthalmology, focused on treating degenerative eye disorders that primarily affect the elderly. AMD is one of the leading causes of vision loss among people aged 50 and above. With the increasing geriatric population and rising awareness about early diagnosis, the demand for AMD treatments is witnessing significant growth.

In 2024, the global AMD market was valued at USD 10.46 Billion and is expected to grow at a CAGR of 9.70%, reaching USD 26.40 Billion by 2034. Similar to the breath analyzer market, which emphasizes timely detection and accuracy in respiratory assessments, the AMD market emphasizes early detection, targeted treatment, and advanced therapeutic solutions to preserve vision.

Market Overview

Age-related macular degeneration affects the macula, the central part of the retina, leading to loss of central vision. The market has evolved with the development of anti-VEGF therapies, intravitreal injections, and newer biologics, allowing patients to maintain better vision outcomes.

Key Drivers

• Growing geriatric population prone to AMD

• Increasing prevalence of chronic conditions like diabetes and hypertension

• Technological advancements in retinal imaging and diagnostics

• Rising patient awareness and screening initiatives

• Expanding pipeline of innovative drugs and biologics

Market Size and Growth

• 2024 Market Value: USD 10.46 Billion

• 2034 Projected Value: USD 26.40 Billion

• CAGR (2025–2034): 9.70%

North America currently dominates the AMD market due to advanced healthcare infrastructure, high awareness, and early adoption of anti-VEGF therapies. Europe and Asia Pacific are expected to grow rapidly, driven by rising prevalence, healthcare investments, and improving accessibility of treatments.

Read full report: https://www.expertmarketresearch.com/reports/age-related-macular-degeneration-market/requestsample

Market Breakup by Product

• Wet AMD: Characterized by abnormal blood vessel growth under the retina, leading to rapid vision loss.

• Dry AMD: More common type, progresses slowly and causes gradual central vision loss.

Market Breakup by Drug

• Lucentis: A recombinant monoclonal antibody fragment targeting VEGF-A, widely used for wet AMD.

• Eylea: A VEGF inhibitor effective for both wet AMD and diabetic macular edema.

• Avastin: Originally an oncology drug, used off-label for AMD due to cost-effectiveness.

• Others: Emerging biologics, gene therapies, and combination therapies under clinical investigation.

Market Breakup by Route of Administration

• Intravenous (IV): Less common, used primarily for experimental therapies.

• Intravitreal (IVT): Direct injection into the vitreous humor of the eye, the most common method for anti-VEGF therapies.

Market Breakup by Region

• North America: Dominates due to technological adoption, geriatric population, and reimbursement support.

• Europe: Rapid growth through increased screening, anti-VEGF adoption, and public health initiatives.

• Asia Pacific: High growth potential with rising elderly population and improving healthcare infrastructure.

• Latin America: Emerging market with increasing awareness and accessibility to AMD therapies.

• Middle East and Africa: Gradual adoption due to investment in ophthalmology and healthcare services.

Market Dynamics and Trends

Key Drivers

• Rising Geriatric Population: Aging increases AMD prevalence, fueling treatment demand.

• Technological Advancements: Enhanced retinal imaging, OCT devices, and AI-based diagnostic tools enable early detection.

• Innovative Therapeutics: New anti-VEGF drugs, gene therapy approaches, and sustained-release formulations are transforming AMD management.

• Government Initiatives: Screening programs and insurance coverage for AMD treatments support market growth.

• Patient Awareness: Education campaigns emphasize early detection and timely treatment, boosting therapy adoption.

Challenges

• High Treatment Costs: Anti-VEGF therapies are expensive, limiting access in developing regions.

• Invasive Procedures: Frequent intravitreal injections can affect patient compliance.

• Regulatory Hurdles: Approval timelines for novel therapies can delay market entry.

• Market Fragmentation: Multiple emerging drugs increase competition and complexity.

Recent Developments

• Regeneron Pharmaceuticals launched new anti-VEGF formulations with longer dosing intervals to improve patient adherence.

• Novartis AG expanded manufacturing capabilities for Lucentis to meet increasing global demand.

• Bayer AG invested in research for gene therapy approaches targeting dry AMD.

• AI-based retinal diagnostic tools are being integrated into screening programs in North America and Europe.

Key Players in the Age-Related Macular Degeneration Market

• Bayer AG – Focus on innovative anti-VEGF therapies and gene therapy research.

• F. Hoffmann-La Roche Ltd. – Key player in retinal therapeutics and biologics.

• Novartis AG – Manufacturer of Lucentis, a leading therapy for wet AMD.

• Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) – Known for Eylea and pipeline for extended-duration therapies.

• Others: Emerging biotech companies and local manufacturers contributing to market expansion.

FAQs

Q1. What is the current size of the Age-Related Macular Degeneration market?The AMD market was valued at USD 10.46 Billion in 2024 and is projected to reach USD 26.40 Billion by 2034, growing at a CAGR of 9.70%.

Q2. What factors are driving growth in the AMD market?Market growth is fueled by the increasing geriatric population, rising prevalence of chronic diseases, technological advancements, and the adoption of anti-VEGF therapies.

Q3. Which AMD product segment is most widely used?Wet AMD treatments dominate the market due to rapid progression and high risk of vision loss.

Q4. Which route of administration is preferred for AMD drugs?Intravitreal injections are the most common method for administering anti-VEGF therapies.

Q5. Who are the leading companies in the AMD market?Major players include Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.